Home Newsfeeds CNBC Halftime Report Final Trades: Freeport-McMoRan, Broadcom & Netflix

CNBC Halftime Report Final Trades: Freeport-McMoRan, Broadcom & Netflix

– CNBC

byBenzinga Newsdesk

October 6, 2022

1 minute read

– CNBC

HC Wainwright & Co. Initiates Coverage On Eyenovia with Buy Rating, Announces Price Target of $12

By Benzinga Newsdesk

October 5, 6:11 AM

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Eyenovia (NASDAQ:EYEN) with a Buy rating and announces Price Target of $12.

EYEN

News

AstraZeneca Announced Tezspire Approved in Japan for Severe Asthma

By Charles Gross

September 27, 5:03 AM

AstraZeneca's Tezspire (tezepelumab) has been approved in Japan for the treatment of bronchial asthma in patients with severe or refractory disease in whom asthma symptoms cannot be controlled with mid- or high-dose inhaled corticosteroids and other long-term maintenance therapies.1

AZN

News

EpicQuest Education Announces Davis College And EduGlobal College Sign Memorandums Of Understandings And Recruitment Agreements With ICBT Campus Of Sri Lanka

By Benzinga Newsdesk

September 12, 8:34 AM

MIDDLETOWN, Ohio, Sept. 12, 2022 /PRNewswire/ -- EpicQuest Education Group International Limited ("EpicQuest Education" or the "Company") (NASDAQ: EEIQ), a provider of comprehensive

EEIQ

TRACON Pharmaceuticals Provides Update On Ongoing ENVASARC Pivotal Phase 2 Trial; Objective Response Rate By Investigator Review Increased To 15% Since Interim Analysis In September

By Benzinga Newsdesk

December 20, 9:03 AM

Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024SAN DIEGO, Dec. 20, 2023

TCON

CNBC Halftime Report Final Trades: Freeport-McMoRan, Broadcom & Netflix

Related Posts

HC Wainwright & Co. Initiates Coverage On Eyenovia with Buy Rating, Announces Price Target of $12

AstraZeneca Announced Tezspire Approved in Japan for Severe Asthma

EpicQuest Education Announces Davis College And EduGlobal College Sign Memorandums Of Understandings And Recruitment Agreements With ICBT Campus Of Sri Lanka

TRACON Pharmaceuticals Provides Update On Ongoing ENVASARC Pivotal Phase 2 Trial; Objective Response Rate By Investigator Review Increased To 15% Since Interim Analysis In September